Discover 1,670 paid clinical trials in Atlanta, Georgia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Atlanta’s leading healthcare centers are recruiting participants for studies focused on developing innovative treatments for conditions such as cancer, depression, high blood pressure, and kidney disease. Whether you’re searching for paid clinical research opportunities as a healthy volunteer or trials for specific conditions, Atlanta provides a wide range of research options to meet your needs.
Filter
2
Filter results
Results: 1,670
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
for
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma,
Location: Atlanta GA, Macon GA, Chattanooga TN, Greenville SC,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 25
Code: NCT03959085
Phase 3, Recruiting
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Prism Adaptation Therapy (PAT) for Right Brain Stroke Rehabilitation
for
Spatial Neglect After Right Brain Stroke
Location: Decatur GA, Cleveland OH, West Haven CT, Leeds MA
Sponsor: VA Office of Research and Development
Sex: All
Age: 18+
Code: NCT05983185
Recruiting
Vagal Nerve Stimulation in mTBI
for
PTSD, mTBI
Location: Decatur GA
Sponsor: VA Office of Research and Development
Sex: All
Age: 18 - 55
Code: NCT04437498
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Location: Atlanta GA, Indianapolis IN, Boston MA, Newark NJ,
Sponsor: Theragenics Corporation
Sex: All
Age: 50+
Code: NCT00100087
Phase 1, Phase 2, Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)